CD274 and neoplasm: The Blueprint PD‐L1 IHC assay comparison project18 revealed similar performance on tumor cells staining in three assays (22C3, 28‐8, and SP263) and fewer tumor cells staining in the SP142 assay, with low concordance rates in the scoring of immune cells among the four assays.